CL2014002789A1 - Terapia de combinación de anticuerpos anti-mif y glucocorticoides - Google Patents
Terapia de combinación de anticuerpos anti-mif y glucocorticoidesInfo
- Publication number
- CL2014002789A1 CL2014002789A1 CL2014002789A CL2014002789A CL2014002789A1 CL 2014002789 A1 CL2014002789 A1 CL 2014002789A1 CL 2014002789 A CL2014002789 A CL 2014002789A CL 2014002789 A CL2014002789 A CL 2014002789A CL 2014002789 A1 CL2014002789 A1 CL 2014002789A1
- Authority
- CL
- Chile
- Prior art keywords
- mif
- glucocorticoid
- antibodies
- combination therapy
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624988P | 2012-04-16 | 2012-04-16 | |
| US201261668864P | 2012-07-06 | 2012-07-06 | |
| US201361785626P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002789A1 true CL2014002789A1 (es) | 2014-12-12 |
Family
ID=48190488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002789A CL2014002789A1 (es) | 2012-04-16 | 2014-10-16 | Terapia de combinación de anticuerpos anti-mif y glucocorticoides |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20150250873A1 (es) |
| EP (1) | EP2838559B1 (es) |
| JP (1) | JP6236062B2 (es) |
| KR (1) | KR20150008105A (es) |
| CN (1) | CN104470540B (es) |
| AU (2) | AU2013203957B9 (es) |
| CA (1) | CA2869987A1 (es) |
| CL (1) | CL2014002789A1 (es) |
| ES (1) | ES2779036T3 (es) |
| HK (1) | HK1206984A1 (es) |
| IL (1) | IL235037A0 (es) |
| MX (1) | MX2014012534A (es) |
| NZ (1) | NZ628454A (es) |
| PL (1) | PL2838559T3 (es) |
| RU (1) | RU2014145694A (es) |
| WO (1) | WO2013156472A1 (es) |
| ZA (1) | ZA201507929B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150029017A (ko) | 2012-07-10 | 2015-03-17 | 박스터 헬쓰케어 에스에이 | 항-mif 면역조직화학 |
| US9688635B2 (en) | 2012-09-24 | 2017-06-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN106068456A (zh) * | 2014-01-03 | 2016-11-02 | 百深有限责任公司 | 抗‑mif免疫组织化学 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| EP3802595A1 (en) * | 2018-06-07 | 2021-04-14 | OncoOne Research & Development GmbH | Anti-oxmif/anti-cd3 antibody for cancer treatment |
| EP4069735A1 (en) * | 2019-12-06 | 2022-10-12 | OncoOne Research & Development GmbH | Anti-oxmif/anti-cd3 bispecific antibody constructs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4708510B2 (ja) * | 1993-05-17 | 2011-06-22 | サイトカイン ファーマサイエンシズ,インコーポレーテッド | サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制 |
| US6645493B1 (en) * | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
| WO2001064749A2 (en) * | 2000-02-28 | 2001-09-07 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
| US7205107B2 (en) * | 2001-12-21 | 2007-04-17 | Cytokine Pharmasciences, Inc. | Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease |
| US20070213296A1 (en) * | 2006-03-07 | 2007-09-13 | Yanzhen Zhang | Compositions and methods for the treatment of immunoinflammatory disorders |
| CN100457895C (zh) * | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 |
| US20080287406A1 (en) * | 2007-03-26 | 2008-11-20 | Lessem Jan N | Compositions and methods for treating medical conditions |
| US20090220521A1 (en) * | 2008-01-04 | 2009-09-03 | Randolf Kerschbaumer | Anti MIF Antibodies |
-
2013
- 2013-04-11 AU AU2013203957A patent/AU2013203957B9/en not_active Ceased
- 2013-04-16 PL PL13718822T patent/PL2838559T3/pl unknown
- 2013-04-16 ES ES13718822T patent/ES2779036T3/es active Active
- 2013-04-16 CN CN201380028648.3A patent/CN104470540B/zh not_active Expired - Fee Related
- 2013-04-16 NZ NZ628454A patent/NZ628454A/en not_active IP Right Cessation
- 2013-04-16 MX MX2014012534A patent/MX2014012534A/es unknown
- 2013-04-16 KR KR20147031758A patent/KR20150008105A/ko not_active Withdrawn
- 2013-04-16 WO PCT/EP2013/057892 patent/WO2013156472A1/en not_active Ceased
- 2013-04-16 US US14/394,709 patent/US20150250873A1/en not_active Abandoned
- 2013-04-16 EP EP13718822.3A patent/EP2838559B1/en active Active
- 2013-04-16 HK HK15107625.1A patent/HK1206984A1/xx unknown
- 2013-04-16 RU RU2014145694A patent/RU2014145694A/ru not_active Application Discontinuation
- 2013-04-16 CA CA2869987A patent/CA2869987A1/en active Pending
- 2013-04-16 JP JP2015506211A patent/JP6236062B2/ja active Active
-
2014
- 2014-10-07 IL IL235037A patent/IL235037A0/en unknown
- 2014-10-16 CL CL2014002789A patent/CL2014002789A1/es unknown
-
2015
- 2015-08-07 AU AU2015210447A patent/AU2015210447B2/en not_active Ceased
- 2015-10-26 ZA ZA2015/07929A patent/ZA201507929B/en unknown
-
2017
- 2017-11-01 US US15/801,260 patent/US20180280501A1/en not_active Abandoned
-
2020
- 2020-12-31 US US17/139,772 patent/US20210187105A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1206984A1 (en) | 2016-01-22 |
| WO2013156472A1 (en) | 2013-10-24 |
| AU2013203957B9 (en) | 2015-10-15 |
| CN104470540B (zh) | 2016-08-31 |
| JP6236062B2 (ja) | 2017-11-22 |
| AU2013203957A1 (en) | 2013-10-31 |
| AU2013203957B2 (en) | 2015-09-03 |
| CN104470540A (zh) | 2015-03-25 |
| ES2779036T3 (es) | 2020-08-13 |
| EP2838559B1 (en) | 2019-11-27 |
| CA2869987A1 (en) | 2013-10-24 |
| ZA201507929B (en) | 2017-11-29 |
| EP2838559A1 (en) | 2015-02-25 |
| IL235037A0 (en) | 2014-12-31 |
| MX2014012534A (es) | 2014-11-21 |
| US20180280501A1 (en) | 2018-10-04 |
| NZ628454A (en) | 2015-10-30 |
| JP2015514734A (ja) | 2015-05-21 |
| KR20150008105A (ko) | 2015-01-21 |
| US20150250873A1 (en) | 2015-09-10 |
| PL2838559T3 (pl) | 2020-06-01 |
| AU2015210447B2 (en) | 2016-10-20 |
| US20210187105A1 (en) | 2021-06-24 |
| AU2015210447A1 (en) | 2015-09-03 |
| RU2014145694A (ru) | 2016-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015001321A1 (es) | Anticuerpos anti-ceacam5 y usos de éstos | |
| PL3978522T3 (pl) | Ludzkie przeciwciała przeciwko fel d1 i sposoby ich stosowania | |
| DK2806892T3 (da) | Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser | |
| PL2812443T3 (pl) | Przeciwciała CD47 i sposoby ich zastosowania | |
| PL2922850T3 (pl) | Związki i sposoby ich stosowania | |
| IL263320A (en) | Anti-hemagglutinin antibodies and methods of use | |
| CO7000747A2 (es) | Anticuerpos anti-lrp5 y métodos de uso | |
| ZA201501858B (en) | Anti-mcam antibodies and associated methods of use | |
| BR112014028366A2 (pt) | anticorpos anti-ly6e e imunoconjugados e métodos de uso | |
| SI2858671T1 (sl) | Formulacija protiteles | |
| EP2930714A4 (en) | Singing voice synthesizing system and singing voice synthesizing method | |
| IL227465B (en) | Blockstent device amd methods of use | |
| EA201892584A1 (ru) | Системы и способы для изготовления объемных непрерывных волокон | |
| LT2885010T (lt) | Tautopatijos gydymo būdai | |
| EP2870180C0 (en) | ANTI-BIOTIN ANTIBODIES AND METHODS OF USE | |
| EP3470433C0 (en) | MODIFIED ANTIBODY REGIONS AND THEIR USES | |
| SG11201502757QA (en) | Anti-c16orf54 antibodies and methods of use thereof | |
| EP2925890C0 (en) | ACCELERATED PREDICTION OF CANCER PROGRESSION AND RESPONSE TO TREATMENT | |
| IL234606B (en) | Novel methods and composition for treatment of disease | |
| IL262252B (en) | Therapeutic compositions and methods involving mrna transfection | |
| CL2014002789A1 (es) | Terapia de combinación de anticuerpos anti-mif y glucocorticoides | |
| IL233875A (en) | Composition and use thereof in the treatment of anal rhagades | |
| PT3228313T (pt) | Formas de dosagem e utilizações terapêuticas de l-4-cloroquinurenina | |
| CL2016001327A1 (es) | Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos (divisional de solicitud 2788-14) | |
| EP2811295A4 (en) | SEPARATION AGENT AND METHOD FOR MANUFACTURING SAME |